Zacks Research Upgrades Aytu BioPharma (NASDAQ:AYTU) to “Hold”

Aytu BioPharma (NASDAQ:AYTU) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

AYTU has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Wall Street Zen upgraded Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Finally, Ascendiant Capital Markets lifted their target price on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.33.

Aytu BioPharma Price Performance

AYTU opened at $2.64 on Monday. The company has a market capitalization of $28.33 million, a price-to-earnings ratio of -0.69 and a beta of 0.35. The company has a current ratio of 1.16, a quick ratio of 1.03 and a debt-to-equity ratio of 0.70. Aytu BioPharma has a 12-month low of $0.95 and a 12-month high of $3.07. The business’s fifty day simple moving average is $2.52 and its 200-day simple moving average is $2.33.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.The business had revenue of $15.17 million during the quarter, compared to analysts’ expectations of $12.17 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AYTU. AWM Investment Company Inc. purchased a new stake in Aytu BioPharma in the second quarter valued at about $1,351,000. Stonepine Capital Management LLC increased its holdings in shares of Aytu BioPharma by 75.3% in the second quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock valued at $1,772,000 after purchasing an additional 348,955 shares during the period. FNY Investment Advisers LLC raised its stake in shares of Aytu BioPharma by 24,207.7% in the fourth quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock worth $82,000 after purchasing an additional 31,470 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Aytu BioPharma during the third quarter worth about $58,000. Finally, Two Sigma Investments LP lifted its holdings in shares of Aytu BioPharma by 96.2% during the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares during the period. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.